Colorectal cancer, encompassing malignancies of the colon and rectum, stands as the third most prevalent cancer globally and ranks second in cancer-related mortality [1]. In 2020, over 1.9 million new cases were diagnosed worldwide [2], leading to more than 930,000 deaths [3]. The risk of developing colorectal cancer increases with age, predominantly affecting individuals aged 50 and above.
The growth of colorectal cancer is staged based on the extent of disease spread:
- Stage I: Cancer is localized in the inner layer of the colon or rectum.
- Stage II: Tumor growth deeper into or through the wall of the colon or rectum, but has not reached nearby lymph nodes.
- Stage III: Cancer spreads to nearby lymph nodes.
- Stage IV: Malignancy metastasizes to distant organs, such as the liver or lungs.
Survival rates for colorectal cancer differ depending on the stage at the moment of diagnosis. According to the American Cancer Society [4], the 5-year relative survival rates are approximately 91% for stage I, 85% for stage II, 73% for stage III, and 13% for stage IV [5].
Encouragingly, advancements in medical research have introduced innovative therapies that offer hope, even for advanced-stage colorectal cancer patients. Emerging treatments, including immunotherapies and targeted therapies, are enhancing survival prospects and quality of life. With personalized treatment plans and comprehensive care, many patients are achieving remission and returning to fulfilling lives.
Standard Treatment Protocols for Colorectal Cancer
The treatment algorithm of colorectal cancer is tailored based on the cancer’s stage, tumor location, and the patient’s overall health [6].
Surgery is one of the main treatment approaches for early-stage colorectal cancer. In the stage 1 colorectal cancer treatment guideline, procedures, such as polypectomy or local ressection, can be performed. If the tumor is more advanced and has grown through the wall of the intestine, segmental resections like colectomy or proctectomy are performed to remove the bowel segment with the neoplasm, along with local lymph nodes. Surgery is most effective in stages I to III, where the cancer is localized and has not metastasized. In colorectal cancer treatment by stage, surgical procedures play an important role in giving patients a chance to go into complete remission, and options are based on tumor size, location, and spread.
Chemotherapy is also one of the big parts of colorectal cancer treatment, particularly for later and metastatic cases. When performed on stage III, adjuvant chemotherapy, meaning that it is administered after surgery, has been shown to reduce the risk of cancer recurrence and improve overall survival rates. For colorectal cancer with metastasis, chemotherapy aims to control tumor progression and reduce symptoms, resulting in a better quality of life. Chemotherapeutic treatment plans are personalized based on tumor-specific characteristics and individual patient factors, ensuring a balance between efficacy and tolerability.
Radiation therapy, with the help of high-energy beams, is administered to target and destroy cancer cells. It is used in rectal cancer cases preoperatively to shrink tumors to provide more precise surgical removal and reduce recurrence risks. In colorectal cancer treatment by stage, radiation plays a palliative role and can help with symptoms like bleeding or obstruction.
New and Innovative Colorectal Cancer Treatment Options
Dendritic Cell Therapy for Colorectal Cancer
Dendritic cell therapy is a new treatment for colorectal cancer, especially for patients with advanced or treatment-resistant forms of the malignancy. Dendritic cells are a specialized type of cell called antigen-presenting cells that initiate the immune responses by teaching T-cells to produce antibodies towards cancer. In dendritic cell therapy for colon cancer, these cells are harvested from the patient and, in a laboratory setting, are exposed to tumor-specific antigens. Then they are reintroduced into the patient’s body and immediately start working by initiating the immune response. This process aims to stimulate the immune system to recognize and attack cancer cells more effectively.
The Nobel Prize in Physiology or Medicine was awarded in 2011 to Ralph Steinman for his discovery of dendritic cells and their key role in initiating the immune response [7]. It shows that the method is scientifically recognised, and this laid the groundwork for developing dendritic cell-based immunotherapies.
Research has shown the great results of dendritic cell-based vaccines even in 4 stage bowel cancer treatment. It indicated that combining dendritic cell therapy with standard chemotherapy even more facilitates immune activation in colorectal cancer patients and contributes to tumor regression. That’s why, to improve overall survival rates and quality of life for patients with metastatic colorectal cancer, the combination of therapies is used.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Cancer
HIPEC is a new colorectal cancer treatment procedure that combines open cytoreductive surgery (CRS) with further administration of heated chemotherapy into the abdominal cavity. This treatment is used mainly for patients with metastatic peritoneal cancer. The procedure starts with the surgical removal of visible tumors. Then, the circulation of warmed chemotherapeutic agents is performed within the peritoneal cavity. The heat allows for better penetration of the chemotherapy and, by that, increases its effectiveness. Thanks to the procedure, the microscopic cancer cells that are left after the surgery are being destroyed.
Research indicated that CRS combined with HIPEC can significantly improve survival rates. A systematic review reported a 5-year survival rate increasing from 19% to 51% for patients who received this combined treatment.
Dr. Michael Lipp: "The Future of Complex Cancer Surgery"
If you seek a more in-depth understanding of HIPEC, we advise you to watch a video interview with Professor Michael Lipp, Head of Abdominal and Colorectal Surgery at Asklepios Hospital Barmbek. He dives into this process step-by-step and tells more about patient selection criteria and how HIPEC significantly improves outcomes for individuals with abdominal carcinomatosis.
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Colorectal Cancer
PIPAC is a minimally invasive alternative treatment for colorectal cancer. It is designed for patients with end-stage disease with peritoneal carcinomatosis from colorectal cancer. PIPAC improves standard chemotherapy by delivering drugs in the form of aerosol directly into the peritoneal cavity during laparoscopic surgery. This ensures uniform distribution and helps to penetrate the tissue more deeply. It is also designed for patients who are not appropriate candidates for a large surgical procedure. It is shown that PIPAC is a safe treatment that improves median overall survival, ranging from 8 to 37.8 months. Also, it keeps the patient’s quality of life stable between PIPAC cycles.
Interventional Radiology for Colorectal Cancer
Interventional radiology (IR) has now become a consistent component in the management of patients with colorectal cancer with advanced-stage disease and those who are not candidates for traditional surgery. It is a set of image-guided, minimally invasive procedures and targeted treatments that can effectively control tumor growth but also minimize damage to surrounding healthy tissues.
Thermal ablation is one of the main IR techniques, which includes radiofrequency ablation (RFA) and microwave ablation (MWA). These methods are aimed at destroying the tumor by delivering heat directly to the lesion. This helps to effectively "cook" the malignant tissue at the same time preserving surrounding healthy structures as much as possible. Thermal ablation can achieve local control rates of 80-90% and 5-year overall survival rates exceeding 50% in patients with liver metastases. These techniques are often performed under image guidance (CT or ultrasound) and can be repeated if new lesions appear. They are typically used for tumors less than 3 cm in size and are ideal for patients who are not candidates for surgery due to other health conditions.
Cryoablation is a technique that, with the help of extreme cold, causes the tumor cell apoptosis through ice crystal formation and cellular rupture. It is a particularly great method for tumors located near critical blood vessels or nerves, because it allows for precise control with minimal damage to surrounding tissues. Cryoablation also works with real-time visualization that increases precision. In patients with colorectal cancer, it is used for both curative and palliative purposes. In some cases, it can also stimulate a local immune response against the tumor.
Prof. Kovács on Electrochemotherapy – How Electric Pulses Help Chemo Actually Work
Electrochemotherapy (ECT) combines chemotherapy with electrical pulses to enhance drug uptake by cancer cells, increasing the cytotoxic effect while reducing systemic exposure. The electric pulses temporarily increase cell membrane permeability, allowing chemotherapeutic agents to penetrate cells more efficiently. Clinical studies have demonstrated objective response rates up to 85.7% and a median progression-free survival of approximately 9 months in patients with colorectal cancer liver metastases. ECT is minimally invasive and well-tolerated, making it an excellent option for patients with limited treatment choices. It is often used in combination with other therapies and can be applied to cutaneous, subcutaneous, or internal lesions, including those in the liver or pelvic region.
Stent placement is an IR technique that can be used when the tumor blocks the bowel and causes obstruction. The procedure is image-guided and starts with the placement inside the narrowed part of the rectum the self-expanding metal stent to restore stool passage. It is an important new treatment of colorectal cancer for patients who can’t undergo surgery due to serious comorbidities. It is a palliative treatment for improving the quality of life by reducing symptoms such as pain, bloating, and constipation. Stent placements are performed under local anesthesia due to their minimal invasiveness and have a quick recovery time. This makes it perfect for patients with advanced colon cancer who are not candidates for immediate surgery.
Transarterial chemoembolization (TACE) is an IR technique that targets cancer and metastases by delivering chemotherapy directly to the blood vessels supplying the tumor with further obstruction. This minimizes the systemic side effects and targets cancer more effectively. TACE is one of the main options for patients with liver metastases, especially in stages III and IV, where surgical options may not be that effective. In this case, chemotherapy is administered through a catheter into the hepatic artery feeding the tumor. The embolization provides the blockage of the artery and traps the chemotherapy inside. This approach reportedly has an increased disease control rate of up to 54.3% and a median survival of 47.4 months in patients treated with TACE.
Advantages of Interventional Radiology for Colorectal Cancer
With each improvement in oncology procedures, IR plays a great role in new colorectal cancer treatment, especially for patients with complex or advanced disease. Compared to the traditional surgical procedures, it is minimally invasive. Thanks to that, it has several advantages, including reduced surgical trauma, shorter hospital stays, and faster recovery. Techniques like ablation, chemoembolization, and stent placement are now becoming standard procedures for colorectal cancer treatment, including early interventions in colorectal cancer stage 1 treatment and more aggressive strategies for stage 3 colorectal cancer treatment or even at 4 stage colorectal cancer treatment. These treatments are aimed at sparing as much healthy surrounding tissue as possible, minimizing side effects, and making them highly targeted.
Also, minimally invasive procedures like thermal ablation and laparoscopy-guided therapies can be repeated by an oncologist, which is essential in the cases of advanced and aggressive cancers. IR is a great option for rectal cancer treatment, 4 stage rectal cancer, and rare cases like small bowel cancer treatment or duodenal cancer treatment. It offers a modern solution to problems that conventional methods may not have been able to solve. Also, the combination of IR and systemic therapies, like immunotherapy for bowel cancer, gives patients a chance for much-improved outcomes. The IR use is usually put into the treatment plan by multidisciplinary teams. For a lot of patients, these procedures successfully support long-term remission, transforming standards of oncological care.
| Therapy Type | 2-Year Survival Rate | Response Rate | Duration | Side Effects |
|---|---|---|---|---|
| Standard Treatment | ~25% for advanced cancer | Less than 10% | Several cycles | Severe (nausea, fatigue, hair loss, immunosuppression, skin irritation) |
| Innovative Methods | ~60% for advanced cancer | 45-65% | Up to 4 sessions | Mild (localized discomfort) |
* Booking Health data
Medical Procedures Costs Around the World for Colorectal Cancer
| Treatment Method | GERMANY* | GB | USA |
|---|---|---|---|
| Standard Treatment | €80,000 - €150,000 full course | €90,000 - €165,000 full course | €100,000 - €180,000 full course |
| Innovative Methods | €25,000 - €60,000 full course | €70,000 - €120,000 full course | €100,000 - €150,000 full course |
* Prices may vary depending on the course of treatment and tumor characteristics
Real Colorectal Cancer Patient Story: Success with TACE
Colorectal cancer treatment is a complex thing to deal with, especially in the advanced stages. Let’s look at the case of Sarasibala Premachandran from the United Kingdom, who found hope even when battling a serious disease. She was diagnosed with stage 4 colon cancer and chose to travel to Germany with the help of Booking Health. She had a consultation and went with a treatment plan from Professor Thomas Vogl, one of the leading experts in interventional oncology at the University Hospital in Frankfurt. Sarasibala underwent a TACE procedure, a targeted and minimally invasive interventional radiology procedure directly to liver tumors with further blood supply blockage.
Sarasibala’s daughter, Sughandi, was fascinated by the professionalism and empathy that they received from the very first day. Booking Health was there every step of the way, providing emotional and logistical support – explaining procedures and facilitating doctor-patient communication. This allowed the Premachandran family to focus fully on recovery.
Today, Sarasibala’s prognosis is hopeful. Her experience demonstrates that the right personalized treatment plan, modern technology, and specialists who are leaders in the field can make a difference. For patients like Sughandi, who were diagnosed with stage 4 colorectal cancer, this gives hope and inspires them to keep fighting, especially with the Booking Health team on their side.
Advanced Cancer Treatment: Patient Success Stories with Booking Health
Treating Late-Stage Colorectal Cancer: A Personalized Approach
Getting a diagnosis of advanced or stage 4 colorectal cancer is emotionally overwhelming. Patients often lose hope after hearing: "There is little that can be done". But it is important to keep reaching for help because there are new, effective therapies being developed. Oncology continues to evolve, and alternative treatments for colorectal cancer provide patients with improved survival.
Innovative therapies, such as TACE, HIPEC, and dendritic cell therapy, are giving hope to people who suffer from metastatic disease. These treatments are personalized and target specific tumor characteristics. In contrast to standard protocols, these methods are minimally invasive and have fewer side effects, which result in shorter hospital stays and more time home with family. They give patients a chance to benefit from treatment and do not sacrifice their quality of life.
Here at Booking Health, we are working hard to match patients with the best colorectal cancer treatment centers. We are here to help you receive the best, most innovative, and evidence-based cancer care. When choosing Booking Health as your treatment provider, you will get comprehensive support throughout the entire journey up to recovery.
Even in the most advanced stages, there can be an option that will work just for you. With modern therapies becoming more available, patients who undergo a 4 stage colorectal cancer treatment have meaningful and active lives.
A Medical Journey: Every Step of the Way With Booking Health
Finding the most effective treatment of colorectal cancer can be challenging, especially for patients already fatigued by multiple therapies, conflicting opinions, and complicated medical terminology. With so many standard treatment protocols offering limited success and often accompanied by harsh side effects, patients are frequently left unsure of how to move forward.
This is where Booking Health steps in. As a trusted international medical facilitator with over 12 years of experience in oncology coordination, we help patients worldwide gain access to innovative therapies at the best European hospitals. Our strength lies in building personalized cancer treatment strategies based on each patient's diagnosis, clinical data, and prognosis, ensuring not only advanced care but a path toward better recovery and improved survival rates.
Booking Health provides full-service coordination, including:
- Medical report assessment and expert consultation
- Development of a tailored medical care program
- Selection of a suitable hospital for colorectal cancer treatment
- Preparation and translation of documents
- Communication with treating physicians
- Visa support, flight, and accommodation arrangements
- A personal coordinator and interpreter available 24/7
- Support before, during, and after treatment, including follow-up care in your home country
- Transparent pricing with no hidden costs
Your health is too important to entrust to chance. With Booking Health, you are supported by a professional team dedicated to ensuring the most effective care available, designed around you.
Frequently Asked Questions About Colorectal Cancer
Send request for treatmentColorectal cancer develops in the colon or rectum, both of which are parts of the large intestine. It can arise in any section, including the ascending, transverse, descending, or sigmoid colon, as well as the rectum.
Colorectal cancer is the fourth most common cancer in the U.S., with around 150,000 new cases diagnosed annually. The lifetime risk is approximately 1 in 24 for men and 1 in 26 for women.
Yes, colorectal cancer can be fully cured, especially in early stages. Nowadays, even patients with stage 4 cancer have a chance of long-term remission when using the innovative treatment methods.
A diagnostic process usually starts with a colonoscopy with biopsy. The next steps are CT or MRI, and blood tests, such as CEA tumor markers, that help in cancer staging and characteristics.
Carcinoembryonic antigen (CEA) is a marker for colorectal tumors that can be used in primary diagnosis and to monitor recurrence.
Colorectal cancer usually does not have aggressive growth and progresses slowly over several years. It mostly starts from benign polyps that do not cause any symptoms.
Yes, patients with stage 3 colorectal cancers have a chance to be cured. A comprehensive surgery with lymph node dissection and further chemotherapy shows improved survival.
There is no one-size-fits-all treatment, as it depends on the stage of cancer, location, and the patient's overall health.
The most common options are surgery, chemotherapy, targeted therapies, and immunotherapy. Also, many patients may benefit from innovative techniques such as HIPEC or TACE.
Surgery is the most commonly used treatment, particularly for stages I–III. It is often followed by chemotherapy to eliminate any remaining cancer cells and reduce the risk of recurrence.
Chemotherapy is highly effective, especially in stage 3 and metastatic disease. It can reduce the risk of recurrence after surgery and, in advanced cases, prolong life and improve quality of life.
Surgery is recommended when the cancer is localized and can be completely removed. It is usually the first line of treatment for early-stage disease and may also play a role in selected advanced cases with limited metastases.
Side effects depend on the treatment used. Systemic approaches often cause fatigue, nausea, vomiting, diarrhea, neuropathy, lowered immunity, and changes in appetite.
Targeted therapy works by blocking specific proteins that promote cancer cell growth. They also target certain genetic mutations like RAS, BRAF, and HER2.
Immunotherapy for bowel cancer is used in the form of dendritic cell vaccination. It works by training the immune system to recognize and attack cancer cells. It shows promise in different types of colorectal tumors.
Yes, radiation therapy can be performed in patients with rectal cancer. It helps to shrink the tumor before the surgery or to prevent recurrence after. But it is limited in use depending on the location of the malignancy.
The 5-year relative survival rate is approximately 91% for stage I, 85% for stage II, 73% for stage III, and 13% for stage IV. The earlier the tumor is detected, the more favorable the outcomes.
Yes, there is always a risk of recurrence. But regular follow-ups, including blood tests and imaging, help detect recurrences early when they are most treatable.
Costs vary depending on the stage, location, treatment methods, and treatment center. On average, expenses can range from $25,000 to over $150,000. But generally, receiving treatment in Germany is more affordable than in other countries like the USA or the UK.
Therapies like immunotherapy, combination targeted therapies, and innovative localized treatments like HIPEC, PIPAC, and TACE have been developed and improved in recent years.
Best colorectal cancer treatment options 2026 include dendritic cell immunotherapy, HIPEC, and TACE. They are helping patients to achieve 45-65% response rates compared to less than 10% with standard treatments. It is a new hope for advanced cases.
Oncological teams have significantly improved late colorectal cancer survival rates through modern treatments such as TACE and PIPAC. These minimally invasive approaches have ~60% 2-year survival rates compared to ~25% with conventional protocols.
Colon vs rectal cancer treatment differences, whether or not it is appropriate to have radiation therapy. Rectal cancer often requires preoperative radiation. It helps to shrink tumors, while colon cancer relies mainly on surgery and chemotherapy.
Yes, in some cases, it is possible to treat cancer without surgery. The alternatives are thermal ablation, cryoablation, electrochemotherapy, and TACE. These are minimally invasive techniques that can provide effective tumor control even for a late stage colorectal cancer.
The cost of colon cancer treatment in Europe vs. the USA is really different. Germany offers patients innovative treatments for €25,000-€60,000 versus €1000,000-€150,000 in the USA. Affordable colorectal cancer treatment abroad also adds to excellent patient care, psychological support, and rehabilitation.
Symptoms of colorectal cancer can be nonspecific and include changes in bowel habits, blood in the stool, abdominal discomfort, unexplained weight loss, and fatigue. However, in the early stages, the disease may show no signs, showing the importance of screening.
The 2-year survival rate for advanced colorectal cancer can reach 25% if the patient is treated with standard options. But, with innovative approaches such as HIPEC, TACE, or dendritic cell therapy, survival rates may increase to around 60%.
Standard colorectal cancer treatment involves multiple chemotherapy cycles that can take several months or a few years. On the other hand, innovative therapies like PIPAC, HIPEC, dendritic cell therapy, etc., usually require only one or up to four sessions.
People who are receiving standard therapies for colorectal cancer often report nausea, fatigue, hair loss, and immunosuppression. In comparison, innovative treatments tend to have milder, localized side effects, which significantly improve tolerance.
The response rate to standard chemotherapy for colorectal cancer is typically below 10%. In turn, innovative multimodal therapies achieve response rates of 45-65%, particularly when interventional, immune, and targeted methods are combined.
Colorectal cancer treatment requires a balance between controlling the primary tumor and managing metastases. In Germany, patients can access dendritic cell therapy, HIPEC, PIPAC, interventional radiology, and hyperthermia ㄧ these approaches allow precise targeting of tumors (often achieving results beyond what standard chemotherapy can provide).
Leading hospitals for colorectal cancer focus on combining surgical expertise with cutting-edge therapies. German oncology centers offer advanced treatment options ㄧ enabling individualized plans that adapt to tumor location, stage, and patient response.
Germany is considered one of the best countries for colorectal cancer care due to its availability of advanced interventions. You can have access to dendritic cell therapy, HIPEC, PIPAC, interventional radiology, and hyperthermia, which allows patients to receive personalised treatments.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] World Health Organization, WHO. Colorectal cancer. https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
[2] OncoDaily. Colorectal Cancer: Epidemiology, Pathogenesis, Diagnosis, and Therapeutic Advances. https://oncodaily.com/oncolibrary/cancer-types/colorectal-cancer
[3] Eileen Morgan, Melina Arnold, A Gini et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736. Epub 2022 Sep 8. [DOI] [PubMed]
[4] American Cancer Society. https://www.cancer.org/
[5] Prashanth Rawla, Tagore Sunkara, Adam Barsouk. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019 Jan 6;14(2):89–103. doi: 10.5114/pg.2018.81072. [DOI] [PMC free article]
[6] Cancer Research UK. Treatment options for colon cancer. https://www.cancerresearchuk.org/about-cancer/bowel-cancer/treatment/treatment-colon/treatment-decisions
[7] Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
Read:
New Effective Treatments for Stage 4 Cancer: Innovations in Oncology
Immunotherapy for Cancer Treatment
Dendritic cell therapy in cancer treatment in Germany - Vaccination against cancer
Article menu:
- Standard Treatment Protocols for Colorectal Cancer
- New and Innovative Colorectal Cancer Treatment Options
- Comparative Treatment Table: Colorectal Cancer Treatments Abroad
- Real Colorectal Cancer Patient Story: Success with TACE
- Treating Late-Stage Colorectal Cancer: A Personalized Approach
- A Medical Journey: Every Step of the Way With Booking Health
- Frequently Asked Questions About Colorectal Cancer
Don't know where to start?
Contact Booking Health
